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Abstract
Purpose There is large variability in reported incidence rates of primary brain/CNS tumors across the world, with mostly 
higher rates in higher-income countries. The aim was to compare malignant and benign brain/CNS tumor incidence between 
Zurich (Switzerland), a high-income country, and Georgia, a lower middle-income country.
Methods For the period March 2009 to February 2012, we extracted the following tumors based on topography according to 
ICD-O3: C70.0–C72.9, and C75.1 (pituitary gland). Data were categorized into histology groups based on the WHO 2007 
histological classification. Age-standardized rates per 100,000 person-years were calculated by subgroups.
Results We included 1104 and 1476 cases of primary brain/CNS tumors for Zurich and Georgia, respectively. Mean age of 
patients was significantly lower in Georgia compared to Zurich (50.0 versus 58.3 years). Overall age-standardized incidence 
rates for malignant and benign brain/CNS tumors were 10.5 (95% CI 9.9–11.0) for Georgia and 23.3 (95% CI 21.9–24.7) for 
Zurich with a ratio of benign to malignant tumors of 1.656 for Georgia and 1.946 for Zurich. The most frequent histology 
types were meningiomas in both regions, followed by glioblastomas in Zurich, but pituitary tumors in Georgia.
Conclusion Age-adjusted incidence rates of brain/CNS tumors were considerably higher in Zurich compared to Georgia, 
both for benign and malignant tumors, which is in line with other studies reporting higher rates in high-income than in low- 
and middle-income countries. The frequency distribution may be related to differences in diagnosing techniques and the 
population age structure.
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Introduction
Primary brain and central nervous system (brain/CNS) 
tumors include a collection of neoplasms (gliomas, men-
ingiomas, neuromas etc.) that vary widely by the degree of 
malignancy. Aside from increasing age, high-dose radiation, 
and some hereditary syndromes, no risk factors for these 
tumors have been established and their etiology remains 
largely unknown [1]. They are rather infrequent with respect 
to incidence rates, but mortality is high. Since brain/CNS 
tumors frequently occur at a younger age than other tumors, 
they have a strong impact on years of potential life lost due 
to cancer. In Switzerland, for the years 2003–2007, brain/
CNS tumors ranked 15 with respect to incidence, but second 
with respect to years of potential life lost in men [2].
Data from 39 countries indicate large variability in 
the incidence rates of brain/CNS cancer with a fivefold 
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difference between the highest (mainly in Europe) and the 
lowest rates (mainly in Asia) [3]. The observed variation 
between countries might be partly due to differences in 
health systems infrastructure, access to care, and the avail-
ability of diagnostic services. However, quality and avail-
ability of incidence data in low- and middle-income coun-
tries, e.g. due to differences in registration/reporting, need 
critical consideration as well.
Primary benign and borderline brain/CNS tumors rarely 
invade adjacent tissue and do not metastasize to other parts 
of the body as the more aggressive malignant brain/CNS 
tumors do [4]. This is one of the reasons why most cancer 
registries only collect information on malignant brain/CNS 
tumors. Still, benign brain/CNS tumors can cause serious 
health problems, mainly because of the anatomical loca-
tion, which can cause damage by growing into and putting 
pressure on other parts of the brain, and therefore can be as 
deadly as malignant tumors. As most cancer registries do not 
collect information on benign tumors, Bell et al. estimated 
the incidence of benign brain tumors by using the US ratio 
of benign to malignant brain tumors of 2.114 [5]. However, 
they also stated that this rate might differ geographically due 
to genetic and environmental factors.
The main aim of our study was to compare brain/CNS 
tumor incidence between a cancer registry in Switzerland, 
a high-income country with a universal health care system 
that provides basic health care for all, and Georgia, a former 
Soviet republic that became independent in 1991 and is con-
sidered a lower middle-income country by the World Bank 
(https ://data.world bank.org/?locat ions=GE-XN). Since 
information on differences between countries of different 
economic development are rare, we put a specific focus on 
differences in the incidence of benign brain/CNS tumors.
Methods
Zurich cancer registry
Zurich is the largest canton in Switzerland with a popula-
tion of about 1.5 million in 2017 [6]. The Cancer Registry 
Zurich, Zug, Schaffhausen and Schwyz was established in 
1980 in the canton of Zurich. Since 2011, it also registers 
cancer cases for the canton of Zug and since 2020 for the 
cantons of Schaffhausen and Schwyz. Each year, about 120 
incident malignant brain/CNS tumors and about 200 benign 
tumors are registered in the canton of Zurich. The regis-
try receives notifications (patient information, tumor char-
acteristics) from pathology and hematology laboratories, 
hospitals, and physicians as well as death certificates from 
the Swiss Federal Statistical Office [7]. A completeness of 
93.4% for brain/CNS tumors three years after diagnosis was 
estimated for Zurich [8], which is above the international 
level for satisfactory completeness of 90%.
Georgia brain tumor registry
The Georgian Brain Tumor Data Bank was established in 
2008 by one author (DG) and team from the Department of 
Neurology & Neurosurgery at the Tbilisi State University 
and was supported by Rustaveli National Science Founda-
tion. Georgia had a population of about 3.7 million in 2018 
(https ://ec.europ a.eu/euros tat/docum ents/40316 88/96841 46/
KS-01-19-056-EN-N.pdf/c3f88 11c-3793-48aa-befa-b8ad7 
53f11 31). Data were collected between March 1, 2009 and 
February 29, 2012 from fifteen different hospitals, which 
provide neurosurgical and neuroradiological services and 
numerous ambulatory-based CT and MRI units in three 
large cities (Tbilisi, Kutaisi and Batumi). Active case ascer-
tainment captured all cases of newly diagnosed brain/CNS 
tumors. More information about case ascertainment and pro-
cedures has been published previously [9, 10].
Data extraction and classification
We extracted the following tumors based on topography of 
primary sites according to ICD-O3: C70.0–C72.9 and C75.1 
(pituitary gland). For Georgia, also tumors of topography 
C75.2 (craniopharyngeal duct, morphology code 9350) were 
included. These are not systematically registered in Zurich 
and were therefore excluded from the Zurich dataset. How-
ever, we wanted to be as complete as possible for Georgia 
and therefore included them in the Georgian data.
We compared incidence of brain/CNS tumors for the 
period March 1, 2009 to February 29, 2012. The dataset 
includes information on sex, date of diagnosis, age at diag-
nosis, ICD-10 code, topography, morphology, and behavior.
Data were categorized into histology groups based on 
the WHO 2007 histological classification [11], which has 
also been used in the analyses of the Central Brain Tumor 
Registry of the United States (CBTRUS) [12]. Furthermore, 
gliomas were defined as a group of neuroepithelial tissue 
tumors including all types of astrocytomas, glioblastomas, 
oligodendrogliomas, oligoastrocytomas, and ependymomas 
according to CBTRUS [12].
Statistical analysis
Age standardization was performed based on five-year age 
groups across the whole age spectrum (18 groups from 0–4 
to 85 + years) and standardized to the US 2000 population 
[13] in order to provide direct comparability of our inci-
dence rates to those of CBTRUS [12]. CBTRUS represents 
one of the largest datasets of primary brain tumors in the 
world. In Online Resource 1, incidence rates were further 
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adjusted to the World standard population [14], the WHO 
standard population [14], and the European standard popu-
lation (1976) [15] for comparison with studies using one 
of these standard populations. Age-standardized rates per 
100,000 person-years were calculated. For the denominator, 
we used the populations of Georgia und Zurich, respectively, 
summed over the years 2009, 2010 and 2011.
All analyses were performed using STATA 13 (Stata Cor-
poration, College Station, TX; USA). The t test for continu-
ous and the χ2 test for categorical data were used to compare 
the patient and tumor characteristics between countries. The 
command “distrate” was used to calculate age-standardized 
incidence rates overall and for sub groups of the study popu-
lation [16]. In addition to age-standardized rates, this com-
mand calculates efficient interval estimates using formulas 
developed by Tiwari et al. [17]. Standardized incidence rate 
ratios (SRR) and 95% confidence intervals were used to 
compare rates between sub groups according to the method 
described by Boyle and Parkin [18].
Results
Characteristics
Table 1 displays the patient and tumor characteristics. 1104 
and 1476 cases of primary brain/CNS tumors were included 
in the study for Zurich and Georgia, respectively. Mean age 
of patients was significantly lower in Georgia compared to 
Zurich (50.0 versus 58.3 years). In both regions, the pro-
portion of female patients was higher than the proportion 
of male patients. The proportion of malignant tumors was 
around one third in both regions, but the percentage of glio-
mas among all brain tumors was higher in Zurich than in 
Georgia (31.7% vs 19.3%, Table 1). Stratification by tumor 
behavior and sex revealed a similar distribution of benign/
borderline and malignant tumors in men, whereas in women, 
the proportion of benign/borderline tumors was more than 
twice (Georgia) or three times (Zurich) as high as the pro-
portion of malignant tumors.
In Zurich, 4.1% of the brain/CNS tumors were not histo-
logically classified (morphology code 8000); this proportion 
was 42.3% in Georgia. The proportion of histologically veri-
fied cases was 52.0% for benign/borderline and 86.5% for 
malignant brain/CNS tumors in Zurich (overall 63.6%). In 
Georgia, overall 37.0% of cases were histologically verified.
Incidence rates
The age-adjusted incidence rates of primary malignant and 
non-malignant brain/CNS tumors in Zurich and Georgia 
were 23.3 and 10.5 per 100,000 person-years, respectively 
(Table 2). While the incidence rate for men and women was 
not significantly different in Georgia, women had a signifi-
cantly higher incidence rate compared to men in Zurich. In 
both regions, the incidence rate for benign/borderline tumors 
Table 1  Descriptive 
characteristics of brain/CNS 
tumor data from Georgia and 
Zurich (Switzerland), March 1, 
2009 to February 29, 2012




Total number of cases 1476 1104
Mean age (years (SD)) 1468 50.0 (17.7) 1104 58.3 (19.5) < 0.001
Sex, N (%) 1391 1104
 Male 588 (42.3%) 470 (42.6%) 0.88
 Female 803 (57.7%) 634 (57.4%)
Tumor behavior, N (%) 608 1104 0.08
 Benign/borderline 378 (62.2%) 733 (66.4%)
 Malignant 230 (37.8%) 371 (33.6%)
Gliomas, N (%) 855 1104 < 0.001
 Glioma 165 (19.3%) 350 (31.7%)
 No glioma 690 (80.7%) 754 (68.3%)
Tumor behavior by sex, N (%) 1383 1104
 Male benign/borderline  126 (9.1%) 246 (22.3%)
 Male malignant  119 (8.6%) 224 (20.3%)
 Male unspecified  340 (24.6%) –
 Female benign/borderline  239 (17.3%) 487 (44.1%)
 Female malignant  111 (8.0%) 147 (13.3%)
 Female unspecified  448 (32.4%) –
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was significantly higher than the one for malignant tumors, 
with a ratio of benign/borderline to malignant tumors of 
1.946 in Zurich and of 1.656 in Georgia. However, simul-
taneous stratification by tumor behavior and sex revealed 
a similar incidence rate irrespective of tumor behavior in 
men, whereas in women, the incidence rates were more than 
twice (Georgia) and three times (Zurich) as high for benign/
borderline compared to malignant tumors. Online Resource 
1 shows the age-adjusted incidence rates using different 
standard populations to allow for a comparison with pub-
lished data from other regions.
Incidence rates and distribution of histology 
subtypes
Crude and age-adjusted incidence rates for each histology 
group according to WHO 2007 histological classification 
are shown in Table 3 for Georgia and Table 4 for Zurich. 
The most frequent histology type were meningiomas in 
both regions (39.4% in Zurich versus 43.7% in Georgia, 
Fig. 1), followed by glioblastomas in Zurich (19.6%)/pitui-
tary tumors in Georgia (22.5%), and nerve sheath tumors 
in Zurich (10.7%)/glioblastoma in Georgia (8.4%).
Among gliomas, glioblastoma was the most frequent 
type (61.7% in Zurich versus 43.6% in Georgia, respec-
tively; Fig. 2). Glioblastoma combined with all other astro-
cytoma types accounted for approximately three-fourth of 
gliomas in both regions (77.4% in Zurich versus 72.1% in 
Georgia).
Incidence rates by sex and histology subtypes
Overall incidence of brain tumors was higher in women 
than in men, although this difference was only signifi-
cant in Zurich (25.3 vs 21.1 per 100,000 person-years; 
Tables 3 (Georgia) and 4 (Zurich)). The incidence rates 
for all neuroepithelial tumors were higher in men than 
in women; however, the difference was only statistically 
significant for Zurich. A higher incidence rate in men was 
also observed for glioblastomas, but the difference was not 
statistically significant in either region. In both regions, 
the incidence rates for meningiomas were higher in women 
Table 2  Age-adjusted incidence rates of brain/CNS tumors in Geor-
gia and Zurich (Switzerland), March 1, 2009 to February 29, 2012
AIR age-adjusted incidence rate per 100,000 person-years (adjusted to 
the US 2000 standard population), 95% CI 95% confidence intervals 
(based on the gamma distribution proposed by Tiwari et al. [17])
Georgia Zurich
AIR 95% CI AIR 95% CI
Overall 10.5 9.9, 11.0 23.3 21.9, 24.7
Sex
 Men 9.2 8.5, 10.0 21.1 19.2, 23.2
 Women 10.5 9.7, 11.2 25.3 23.3, 27.4
Tumor behavior
 Benign/borderline 2.7 2.4, 3.0 15.4 14.3, 16.6
 Malignant 1.6 1.4, 1.9 7.9 7.1, 8.8
 Unspecified 6.1 5.7, 6.6 –
Tumor behavior by sex
 Men benign/borderline 2.0 1.7, 2.4 11.0 9.7, 12.5
 Men malignant 1.9 1.6, 2.3 10.1 8.8, 11.5
 Men unspecified 5.3 4.8, 5.9 – –
 Women benign/border 3.2 2.8, 3.6 19.1 17.4, 21.0
 Women malignant 1.4 1.2, 1.7 6.1 5.1, 7.2
 Women unspecified 5.9 5.3, 6.5 –
Fig. 1  Proportion of different histology subtypes for Georgia and Zurich (Switzerland), March 1, 2009 to February 29, 2012
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than in men, but only statistically significant in Zurich. We 
found no significant difference between men and women 
for pituitary adenomas.
Age distribution
In Zurich, incidence rates by age were clearly increasing 
for all tumors and for meningiomas specifically, which was 
not the case in Georgia (Online Resource 2). Nevertheless, 
we observed a plateau of rates between the age of 40 and 
80 years except for meningiomas and glioblastomas.
Discussion
Our study showed large differences in the incidence of 
malignant and benign brain/CNS tumors between Georgia, 
a lower middle-income country, and Zurich (Switzerland), 
situated in a high-income country. Differences in incidence 
rates with higher rates in higher income countries than in 
low- and middle-income countries have been reported pre-
viously [3, 5, 19]. According to a systematic analysis of the 
global burden of brain/CNS cancer, the percentage change 
in age-standardized rates between 1990 and 2016 was clearly 
higher in high-income compared to low-income countries 
[20].
These differences may be attributable to population 
genetics, oncogenic environmental exposures, healthcare 
access, diagnostic practice, or registry reporting [5]. Spe-
cifically, differences in case ascertainment likely explain a 
large part of the reported variation, with patients in lower-
income countries having reduced access to advanced imag-
ing technology [4, 5]. Switzerland has a mandatory universal 
basic health insurance and high medical and technological 
standards. In Georgia, after 2006 governmental budget was 
used to finance health care for the poorest households only. 
A medical insurance program was rolled out nation-wide in 
2008 also targeting households registered as living below 
the poverty line. For those above the poverty line, state-
funded programs were introduced offering specific services, 
which partially include brain tumor (surgery and palliative 
care). The government introduced a universal health care 
program extending the population and services covered only 
in 2013. Thus, the healthcare system in Georgia was not uni-
versal during the study period (2009–2012), which may have 
biased data collection due to the limited resources.
The most frequent histology type among all registered 
brain/CNS tumors in both regions were meningiomas 
(43.7% in Georgia and 39.4% in Zurich). However, the sec-
ond frequent histology subtype in Georgia were tumors of 
the pituitary (22.5% versus 8.3% in Zurich), while in Zurich 
glioblastomas ranked second (19.6% versus 8.4% in Geor-
gia). The lower rate of verified glioblastoma in Georgia 
may be due to a lack of services for the older population, 
specifically those living in rural areas, including a lack of 
information, caregiving, diagnostic services, and generally 
limited resources. The proportional distribution of glioma 
subtypes also differed between the regions, with higher pro-
portions of glioblastomas and ependymomas in Zurich und 
higher proportions of astrocytomas and oligodendrogliomas 
in Georgia. We can speculate that histologically unclassi-
fied tumors in Georgia may include cases of glioblastoma, 
which usually affect people in the highest age group. On 
the other hand, astrocytomas and oligodendrogliomas are 
most frequently observed in individuals aged between 30 
Fig. 2  Proportion of different glioma subtypes for Georgia and Zurich (Switzerland), March 1, 2009 to February 29, 2012
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and 40 years, where more resources, support and attention 
are available than for older population groups.
The comparison of the incidence rates by histological 
group (Tables 3 and 4) may be influenced by the high pro-
portion of unclassified tumors in Georgia (621 out of 1476). 
However, excluding unclassified tumors would considerably 
decrease the overall incidence rate in Georgia and would not 
be in accordance with the main aim of this study to compare 
overall incidence of brain/CNS tumors between Georgia and 
Switzerland.
While the age-stratified incidence rates increased with 
age in Zurich with highest rates in the oldest age group 
(≥ 80 years), we observed the highest incidence rates in 
Georgia for individuals aged 60–79 years. This may also 
be related to the lack of service for the older population, as 
mentioned above, which results in an underestimation of 
cases in that age group. In addition, social stigma, geopoliti-
cal issues, and cultural norms may limit access to adequate 
cancer care in Georgia, including cancer detection, diagnosis 
and treatment, especially in the elderly. Therefore, cultural 
differences, in addition to cancer care infrastructure and 
workforce capacity constraints, need to be taken into account 
when interpreting the differences between the two regions.
The ratio of benign to malignant brain/CNS tumors 
was 1.946 for Zurich, which is similar to the ratio of 2.114 
reported for the US [5]. For Georgia, this ratio was lower 
(1.656), however, there were quite a few tumors with 
unspecified behavior which may have influenced this ratio.
Comparison with other studies
The comparison of incidence rates between different 
countries and regions using other published studies is not 
straightforward due to different standard populations used 
for age-standardization and differences regarding the defini-
tion and inclusion of brain/CNS tumors.
The incidence rate of malignant brain/CNS tumors in 
Zurich (7.9 [95% CI 7.1–8.8] per 100,000 person-years 
using the US standard population) is comparable to rates 
reported for Europe (6.76 [95% CI 6.71–6.80]) [5], and the 
one adjusted to the WHO standard population (6.9 [95% 
CI 6.1–7.7]) is comparable to rates reported for Western 
Europe (5.84 [95% CI 5.77–5.92]) [19]. On the other hand, 
the WHO age-standardized incidence rate for Georgia 
(malignant brain/CNS tumors only, 1.5 [95% CI 1.3–1.7]) 
is considerably lower compared to rates reported for Eastern 
Europe and Central Asia (4.82 [95% CI 4.76–4.89]) [19], 
but only slightly lower than reported for Iran (2.74 [95% CI 
2.62–2.86]) [21].
The overall age-standardized incidence rate for all 
brain/CNS tumors in Zurich (23.3 [95% CI 21.9–24.7] per 
100,000 person-years) is in a similar range as reported in 
the CBTRUS report for the United States (21.42 [95% CI 
21.35–21.49]) [12] but higher than in France (15.95 per 
100,000 person-years) [22]. However, some tumors were 
excluded from the French data (such as pituitary tumors) 
and the time period investigated in France was earlier 
(2000–2007) [22].
The overall age-standardized incidence rate for all brain/
CNS tumors in Georgia (10.5 [95% CI 9.9–11.0] per 100,000 
person-years) is comparable to the mean worldwide rate of 
10.82 (95% CI 8.63–13.56) [23]. In that study, results var-
ied between 1.88 per 100,000 person-years for Jordan and 
25.95 per 100,000 person-years for Italy [23]. Thus, while 
the rate for Georgia is in line with the world average, the 
rate for Zurich is in the range of countries with the highest 
reported rates.
Using the world standard population for adjustment, 
the age-standardized incidence rate for malignant brain/
CNS tumors of 6.5 (95% CI 5.8–7.3; Online Resource 1) 
for Zurich is comparable to rates reported for other parts 
of Switzerland (7.7 [95% CI 6.9–8.4] for men and 5.5 [95% 
CI 4.8–6.1] for women) and other parts of Western Europe 
[3]. On the other hand, the age-standardized incidence rate 
for Georgia (using the world standard population) of 1.4 
(95% CI 1.2–1.6) was again considerably lower than rates 
reported for other Eastern European countries (including 
Russia; between 6.2 and 9.8 for men and between 4.5 and 
9.2 for women) [3] and Estonia (8.5 [95% CI 8.0–8.9]) [24].
Using the European standard population for adjustment, 
the rates for Zurich (14.7 [95% CI 13.7–15.9] for benign and 
7.9 [95% CI 7.1–8.8] for malignant tumors) were slightly 
higher compared to data from a larger part of Switzerland 
(9.69 for benign, 6.64 for malignant) [4]. The difference 
in incidence rates for benign/borderline versus malignant 
tumors in men and women has also been reported for other 
parts of Switzerland [4].
Strengths and limitations
This study allows for the direct comparison between brain/
CNS tumor rates in a lower middle-income country and a 
high-income country using the same definitions and criteria.
A limitation is the relatively low proportion of histologi-
cally verified cases in Georgia (37%), which is consider-
ably lower than in Zurich (64%) and other countries such as 
France (79%) [22], and the US according to CBTRUS (62% 
overall, 85% for malignant, 50% for non-malignant tumors) 
[12]. However, lower rates of histologically verified cases 
have been reported in other European countries such as Cro-
atia (57.2%) [25], Italy (49%) [26] or Spain (59%) [27]. We 
can assume that primary brain tumor cases found in relevant 
medical documentations are almost complete in the Geor-
gian registry, but the number of histologically unclassified 
cases is high. These were mostly registered from radiologi-
cal (CT, MRI) reports, but were not available in any other 
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hospital data. In a few cases, the histology reports were just 
missing in medical records at the moment of data retrieving. 
It is therefore likely that the true incidence is higher than the 
reported rates in Georgia, primarily in subgroups (by behav-
ior or histology). Finally, tumors of topography C75.2 were 
included for Georgia but are not systematically registered in 
Zurich and were thus excluded for Zurich. However, these 
only accounted for 1.3% of all brain/CNS tumors in Georgia, 
and because we wanted to be as complete as possible for the 
Georgian data, we included them.
Conclusions
We observed considerably higher incidence rates of brain/
CNS tumors in Zurich compared to Georgia, both for benign 
and malignant tumors. These observations are in line with 
other publications reporting higher rates in high-income 
countries and lower rates in low- and middle-income coun-
tries [3, 5, 19]. Meningiomas accounted for the largest pro-
portion in both regions (around 40%), whereas the second 
most frequent tumors were pituitary tumors in Georgia, but 
glioblastomas in Zurich (around 20% each). The frequency 
distribution may be related to differences in diagnosing 
techniques and the population age structure. The incidence 
rates by age group increased in Zurich with highest rates in 
the oldest age group (≥ 80 years), but the highest rates in 
Georgia were seen for individuals aged 60–79 years, which 
may reflect the lack of service for the older rural population 
in Georgia, resulting in an underestimation of cases in the 
oldest age group.
Acknowledgements Open access funding provided by University of 
Zurich.
Author contributions Sabine Rohrmann and David Gigineishvili 
designed the study; Dimitri Korol, Nino Shenglia, Teimuraz Gigineish-
vili and David Gigineishvili were involved in data collection; Miriam 
Wanner and David Gigineishvili analyzed the data; Sabine Rohrmann, 
Dimitri Korol, David Gigineishvili and Miriam Wanner interpreted the 
results; Miriam Wanner, Sabine Rohrmann and David Gigineishvili 
wrote the first draft of the manuscript. All authors read and commented 
previous versions of the manuscript and approved the final manuscript.
Funding This study was funded by a Seed Funding Grant from the 
Swiss State Secretariat for Education, Research and Innovation (SFG 
861), which was used for research visits in Zurich and Georgia. No 
funding was received for the salary of the authors.
Data availability The data are not publicly available.
Code availability The STATA code is available upon request from the 
corresponding author.
Compliance with ethical standards 
Conflict of interest The authors have no conflict of interest.
Open Access This article is licensed under a Creative Commons Attri-
bution 4.0 International License, which permits use, sharing, adapta-
tion, distribution and reproduction in any medium or format, as long 
as you give appropriate credit to the original author(s) and the source, 
provide a link to the Creative Commons licence, and indicate if changes 
were made. The images or other third party material in this article are 
included in the article’s Creative Commons licence, unless indicated 
otherwise in a credit line to the material. If material is not included in 
the article’s Creative Commons licence and your intended use is not 
permitted by statutory regulation or exceeds the permitted use, you will 
need to obtain permission directly from the copyright holder. To view a 
copy of this licence, visit http://creat iveco mmons .org/licen ses/by/4.0/.
References
 1. Bondy ML, Scheurer ME, Malmer B, Barnholtz-Sloan JS, 
Davis FG, Il’yasova D, Kruchko C, McCarthy BJ, Rajaraman P, 
Schwartzbaum JA, Sadetzki S, Schlehofer B, Tihan T, Wiemels 
JL, Wrensch M, Buffler PA, Brain Tumor Epidemiology C (2008) 
Brain tumor epidemiology: consensus from the Brain Tumor Epi-
demiology Consortium. Cancer 113(7 Suppl):1953–1968. https ://
doi.org/10.1002/cncr.23741 
 2. Arndt V, Feller A, Hauri D, Heusser R, Junker C, Kuehni C, 
Lorez M, Pfeiffer V, Roy E, Schindler M (2016) Swiss Cancer 
Report 2015: current situation and developments. NICER, BFS 
und SKKR, Neuchâtel
 3. Miranda-Filho A, Pineros M, Soerjomataram I, Deltour I, Bray F 
(2017) Cancers of the brain and CNS: global patterns and trends in 
incidence. Neuro Oncol 19(2):270–280. https ://doi.org/10.1093/
neuon c/now16 6
 4. Lorez M, Nanieva R, Arndt V, Rohrmann S, Group NW (2018) 
Benign and malignant primary brain tumours in the Swiss popula-
tion (2010–2014). Swiss Cancer Bull 38(2):188–196
 5. Bell JS, Koffie RM, Rattani A, Dewan MC, Baticulon RE, Qureshi 
MM, Wahjoepramono EJ, Rosseau G, Park K, Nahed BV (2019) 
Global incidence of brain and spinal tumors by geographic region 
and income level based on cancer registry data. J Clin Neurosci 
66:121–127. https ://doi.org/10.1016/j.jocn.2019.05.003
 6. Statistical Office of the Canton of Zurich (2019) Statistisches Jahr-
buch des Kantons Zürich 2019 (Statistical Annual Report of the 
Canton of Zurich 2019). Statistical Office of the Canton of Zurich, 
Zurich
 7. Wanner M, Matthes KL, Korol D, Dehler S, Rohrmann S (2018) 
Indicators of data quality at the Cancer Registry Zurich and 
Zug in Switzerland. Biomed Res Int 2018:7656197. https ://doi.
org/10.1155/2018/76561 97
 8. Lorez M, Bordoni A, Bouchardy C, Bulliard JL, Camey B, Dehler 
S, Frick H, Konzelmann I, Maspoli M, Mousavi SM, Rohrmann 
S, Arndt V (2017) Evaluation of completeness of case ascertain-
ment in Swiss cancer registration. Eur J Cancer Prev. https ://doi.
org/10.1097/CEJ.00000 00000 00038 0
 9. Gigineishvili D, Shengelia N, Shalashvili G, Rohrmann S, Tsis-
karidze A, Shakarishvili R (2013) Primary brain tumour epide-
miology in Georgia: first-year results of a population-based study. 
J Neurooncol 112(2):241–246. https ://doi.org/10.1007/s1106 
0-013-1054-1
 10. Gigineishvili D, Gigineishvili T, Tsiskaridze A, Shakarish-
vili R (2014) Incidence rates of the primary brain tumours in 
282 Journal of Neuro-Oncology (2020) 149:273–282
1 3
Georgia: a population-based study. BMC Neurol 14:29. https ://
doi.org/10.1186/1471-2377-14-29
 11. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jou-
vet A, Scheithauer BW, Kleihues P (2007) The 2007 WHO clas-
sification of tumours of the central nervous system. Acta Neuro-
pathol 114(2):97–109. https ://doi.org/10.1007/s0040 1-007-0243-4
 12. Ostrom QT, Gittleman H, Liao P, Rouse C, Chen Y, Dowling 
J, Wolinsky Y, Kruchko C, Barnholtz-Sloan J (2014) CBTRUS 
statistical report: primary brain and central nervous system tumors 
diagnosed in the United States in 2007–2011. Neuro Oncol 
16:iv1–63. https ://doi.org/10.1093/neuon c/nou22 3
 13. Klein RJ, Schoenborn CA (2001) Age adjustment using the 2000 
projected US population. Healthy People 2010 Stat Notes 20:1–10
 14. Ahmad OB, Boschi-Pinto C, Lopez AD, Murray CJL, Lozano 
R, Inoue M (2001) Age standardization of rates: a new WHO 
standard. GPE Discussion Paper Series, vol 31. WHO
 15. Waterhouse JAH, Muir CS, Correa P, Powell J (1976) Cancer 
incidence in five continents, vol. III IARC Scientific Publications 
No. 15. IARC, Lyon
 16. Consonni D, Coviello E, Buzzoni C, Mensi C (2012) A command 
to calculate age-standardized rates with efficient interval estima-
tion. Stata J 12(4):688–701
 17. Tiwari RC, Clegg LX, Zou Z (2006) Efficient interval estimation 
for age-adjusted cancer rates. Stat Methods Med Res 15(6):547–
569. https ://doi.org/10.1177/09622 80206 07062 1
 18. Boyle P, Parkin DM (1991) Cancer registration: principles 
and methods. Statistical methods for registries. IARC Sci Publ 
95:126–158
 19. Leece R, Xu J, Ostrom QT, Chen Y, Kruchko C, Barnholtz-Sloan 
JS (2017) Global incidence of malignant brain and other central 
nervous system tumors by histology, 2003–2007. Neuro Oncol 
19(11):1553–1564. https ://doi.org/10.1093/neuon c/nox09 1
 20. Patel AP, Fisher JL, Nichols E, Abd-Allah F, Abdela J, Abdelalim 
A, Abraha HN, Agius D, Alahdab F (2019) Global, regional, and 
national burden of brain and other CNS cancer, 1990–2016: a 
systematic analysis for the Global Burden of Disease Study 2016. 
Lancet Neurol 18(4):376–393. https ://doi.org/10.1016/S1474 
-4422(18)30468 -X
 21. Jazayeri SB, Rahimi-Movaghar V, Shokraneh F, Saadat S, 
Ramezani R (2013) Epidemiology of primary CNS tumors in Iran: 
a systematic review. Asian Pac J Cancer Prev 14(6):3979–3985. 
https ://doi.org/10.7314/apjcp .2013.14.6.3979
 22. Baldi I, Gruber A, Alioum A, Berteaud E, Lebailly P, Huchet 
A, Tourdias T, Kantor G, Maire JP, Vital A, Loiseau H, Gironde 
TRG (2011) Descriptive epidemiology of CNS tumors in France: 
results from the Gironde Registry for the period 2000–2007. 
Neuro Oncol 13(12):1370–1378. https ://doi.org/10.1093/neuon 
c/nor12 0
 23. de Robles P, Fiest KM, Frolkis AD, Pringsheim T, Atta C, St 
Germaine-Smith C, Day L, Lam D, Jette N (2015) The worldwide 
incidence and prevalence of primary brain tumors: a systematic 
review and meta-analysis. Neuro Oncol 17(6):776–783. https ://
doi.org/10.1093/neuon c/nou28 3
 24. Liigant A, Asser T, Kulla A, Kaasik AE (2000) Epidemiology of 
primary central nervous system tumors in Estonia. Neuroepide-
miology 19(6):300–311. https ://doi.org/10.1159/00002 6269
 25. Georgakis MK, Panagopoulou P, Papathoma P, Tragiannidis A, 
Ryzhov A, Zivkovic-Perisic S, Eser S, Taraszkiewicz L, Sekerija 
M, Zagar T, Antunes L, Zborovskaya A, Bastos J, Florea M, Coza 
D, Demetriou A, Agius D, Strahinja RM, Sfakianos G, Nikas I, 
Kosmidis S, Razis E, Pourtsidis A, Kantzanou M, Dessypris N, 
Petridou ET (2017) Central nervous system tumours among ado-
lescents and young adults (15–39 years) in Southern and East-
ern Europe: registration improvements reveal higher incidence 
rates compared to the US. Eur J Cancer 86:46–58. https ://doi.
org/10.1016/j.ejca.2017.08.030
 26. Caldarella A, Crocetti E, Paci E (2011) Is the incidence of brain 
tumors really increasing? A population-based analysis from 
a cancer registry. J Neurooncol 104(2):589–594. https ://doi.
org/10.1007/s1106 0-011-0533-5
 27. Fuentes-Raspall R, Vilardell L, Perez-Bueno F, Joly C, Garcia-Gil 
M, Garcia-Velasco A, Marcos-Gragera R (2011) Population-based 
incidence and survival of central nervous system (CNS) malignan-
cies in Girona (Spain) 1994–2005. J Neurooncol 101(1):117–123. 
https ://doi.org/10.1007/s1106 0-010-0240-7
Publisher’s Note Springer Nature remains neutral with regard to 
jurisdictional claims in published maps and institutional affiliations.
